Angiogenesis Inhibitors

Angiogenesis inhibitors are drugs that block angiogenesis. These drugs are also called anti-angiogenics. Blocking nutrients and oxygen from a tumor can “starve” it. Angiogenesis inhibitors are unique cancer-fighting agents because they block the growth of blood vessels that support tumor growth rather than blocking the growth of tumor cells themselves. The U.S. Food and Drug Administration (FDA) has approved a number of angiogenesis inhibitors to treat cancer. Approved angiogenesis inhibitors include:

  • Axitinib
  • Bevacizumab
  • Cabozantinib
  • Everolimus
  • Lenalidomide
  • Lenvatinib mesylate
  • Pazopanib
  • Ramucirumab


    Related Conference of Angiogenesis Inhibitors

    April 22-23, 2019

    Global Summit on Radiation Therapy & Targeted Tumors

    Vancouver, Canada
    June 12-13, 2019

    22nd Canada Meetings on Radiology & Novel Cancer Therapies

    Montreal, Quebec, Canada

    Angiogenesis Inhibitors Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in